A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Clinical trial NCT02289833 · COMPLETED
Trial details
- NCT number
- NCT02289833
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-12-15
- Primary completion
- 2016-10-25
- Enrollment
- 49
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.